13D Filing: OrbiMed Advisors and Nabriva Therapeutics PLC – ADR (NBRV)

Page 3 of 6 – SEC Filing

SCHEDULE 13D
CUSIP No.  62957M104
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
3,919,600
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
3,919,600
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,919,600
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.6%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
              
____________
*This percentage is calculated based upon 36,691,490 of the Issuer’s Ordinary Shares (as defined below) outstanding, as set forth in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC (as defined below) on November 9, 2017.

Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)